GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid

By /

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug conjugate in multiple myeloma.

Scroll to Top